Sivelestat

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sivelestat
Sivelestat.svg
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
IV
ATC code
  • None
Legal status
Legal status
  • US: Not approved
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C20H22N2O7S
Molar mass 434.46 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Sivelestat (INN, research name ONO 5046, marketed as Elaspol) is an inhibitor of human neutrophil elastase.[1]

It is used in the treatment of acute respiratory failure[2] and preliminary studies show it may also improve neuropathic pain.[3]

Synthesis[edit]

Sivelestat is synthesised as follows:[4]

Sivelestat scheme.png

References[edit]

  1. ^ Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T (June 1991). "ONO-5046, a novel inhibitor of human neutrophil elastase". Biochem. Biophys. Res. Commun. 177 (2): 814–20. PMID 2049103. doi:10.1016/0006-291X(91)91862-7. 
  2. ^ Imokawa S, Mori K, Harada M, et al. (June 2008). "[Acute respiratory failure due to pneumocystis pneumonia successfully treated with combined use of sivelestat sodium hydrate]". Nihon Kokyuki Gakkai Zasshi (in Japanese). 46 (6): 461–5. PMID 18592991. 
  3. ^ Weyer, Andy D.; Stucky, Cheryl L. (May 2015). "Repurposing a leukocyte elastase inhibitor for neuropathic pain". Nature Medicine. 21 (5): 429–430. ISSN 1078-8956. PMID 25951529. doi:10.1038/nm.3861. 
  4. ^ K. Imaki, Y. Arai, T. Okegawa, U.S. Patent 5,017,610 (1991).